Clinicopathological Characteristics for NSCLC Harboring EGFR Exon 20 Insertion

被引：0
|
作者：
Morikawa, K. [1 ]
Kakinuma, K. [1 ]
Inoue, T. [1 ]
Mineshita, M. [1 ]
机构：
[1] St Marianna Univ, Sch Med, Kawasaki, Kanagawa, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
EGFR-mutant NSCLC; Exon; 20; insertion;
D O I：
10.1016/j.jtho.2019.08.1032
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.09-03
引用
收藏
页码：S496 / S496
页数：1
相关论文
共 50 条
  • [31] Treatment of Nivolumab Results in Hyperprogressive Disease in a Patient Harboring EGFR Exon 20 Insertion and MYC Amplification
    Huang, Xiu
    Xia, Lexin
    Lan, Fen
    Shao, Yang W.
    Li, Wen
    Xia, Yang
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (09) : E189 - E191
  • [32] Clinical outcomes for EGFR/HER2 exon 20 insertion-mutated NSCLC
    Li, K.
    Bosdet, I.
    Yip, S.
    Ho, C.
    Laskin, J.
    Melosky, B.
    Wang, Y.
    Sun, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1058 - S1059
  • [33] Clinical Response to Osimertinib in a Patient with Metastatic NSCLC Harboring EGFR A763_Y764insFQEA Exon 20 Insertion Mutation: A Case Report
    Montenegro, G. Bravo
    Kim, C.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S575 - S576
  • [34] Amivantamab-Vmjw: A Novel Treatment for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutation after Progression on Platinum-Based Chemotherapy
    Shah, Vishal
    McNatty, Andrea
    Simpson, Lacey
    Ofori, Henry
    Raheem, Farah
    BIOMEDICINES, 2023, 11 (03)
  • [35] EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non-Small Cell Lung Cancer
    Leal, Jose Luis
    Alexander, Marliese
    Itchins, Malinda
    Wright, Gavin M.
    Kao, Steven
    Hughes, Brett G. M.
    Pavlakis, Nick
    Clarke, Stephen
    Gill, Anthony J.
    Ainsworth, Hannah
    Solomon, Benjamin
    John, Thomas
    CLINICAL LUNG CANCER, 2021, 22 (06) : E859 - E869
  • [36] A study of the efficacy and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in NSCLC
    Choi, D.
    Jung, H. A.
    Park, S.
    Sun, J-M.
    Ahn, J. S.
    Ahn, M-J.
    Lee, S-H.
    ANNALS OF ONCOLOGY, 2023, 34 : S1696 - S1696
  • [37] Clinico-genomic Characteristics of Patients with Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
    Okahisa, M.
    Udagawa, H.
    Matsumoto, S.
    Kato, T.
    Oizumi, S.
    Furuya, N.
    Hayakawa, D.
    Toyozawa, R.
    Nishiyama, A.
    Ohashi, K.
    Miyamoto, S.
    Nishino, K.
    Oi, H.
    Sakai, T.
    Shibata, Y.
    Izumi, H.
    Sugiyama, E.
    Nosaki, K.
    Zenke, Y.
    Yoh, K.
    Goto, K.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S455 - S456
  • [38] In Vivo, Ex Vivo and Early Clinical Activity of EGFR Monoclonal Antibody and Osimertinib in EGFR Exon 20 Insertion NSCLC
    Riess, J.
    Floch, N.
    Mack, P.
    Martin, M.
    Vang, D.
    Smith, P.
    Cross, D.
    Cheng, M.
    Keck, J.
    Groshen, S.
    Rabin, M.
    Padda, S.
    Oxnard, G.
    Sands, J.
    Ramchandran, K.
    Koczywas, M.
    Moscow, J.
    Janne, P.
    Lara, P.
    Newman, E.
    Gandara, D.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S282 - S282
  • [39] Characterization of EGFR Exon 18 and 20 Mutations in NSCLC
    Farooqi, M.
    Oliver, D.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2014, 16 (06): : 757 - 757
  • [40] Successful Salvage Therapy With a High Dose of Furmonertinib in a Case of Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion
    Jiang, Weizhen
    Sha, Min
    Chen, Cheng
    AMERICAN JOURNAL OF THERAPEUTICS, 2023, 30 (06) : E571 - E573
12345